• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Peripheral Neuropathy Pipeline Review H2 2017

    Diabetic Peripheral Neuropathy Pipeline Review H2 2017

    • Report Code ID: RW0001884132
    • Category Pharmaceuticals
    • No. of Pages 66
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

    "Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, msmoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics."

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 3 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Diabetic Peripheral Neuropathy - Overview
    Diabetic Peripheral Neuropathy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Diabetic Peripheral Neuropathy - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
    Achelios Therapeutics Inc
    Celgene Corp
    Commence Bio Inc
    Grunenthal GmbH
    Immune Pharmaceuticals Inc
    KPI Therapeutics Inc
    Medifron DBT Co Ltd
    Mitsubishi Tanabe Pharma Corp
    Novaremed Ltd
    Reata Pharmaceuticals Inc
    Relief Therapeutics Holding AG
    ViroMed Co Ltd
    Diabetic Peripheral Neuropathy - Drug Profiles
    (amitriptyline + ketamine hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AAD-2004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    atexakin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNV-222 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CMB-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CNV-2197944 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ketoprofen - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KU-32 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MDR-16523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MDR-652 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MT-8554 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NRD-135SE1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDA-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pirenzepine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sodium nitrite SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    U-2902 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VM-202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Diabetic Peripheral Neuropathy - Dormant Projects
    Diabetic Peripheral Neuropathy - Discontinued Products
    Diabetic Peripheral Neuropathy - Product Development Milestones
    Featured News & Press Releases
    Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy
    Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
    Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Celgene Corp, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Novaremed Ltd, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics Holding AG, H2 2017
    Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co Ltd, H2 2017
    Diabetic Peripheral Neuropathy - Dormant Projects, H2 2017
    Diabetic Peripheral Neuropathy - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Achelios Therapeutics Inc
    Celgene Corp
    Commence Bio Inc
    Grunenthal GmbH
    Immune Pharmaceuticals Inc
    KPI Therapeutics Inc
    Medifron DBT Co Ltd
    Mitsubishi Tanabe Pharma Corp
    Novaremed Ltd
    Reata Pharmaceuticals Inc
    Relief Therapeutics Holding AG
    ViroMed Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//diabetic-peripheral-neuropathy-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diabetic-peripheral-neuropathy-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diabetic-peripheral-neuropathy-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments